Article info
PDFOriginal research
Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer
- Correspondence to Dr Angeliki Andrikopoulou, Oncology Unit, Dept of Clinical Therapeutics, National and Kapodistrian University of Athens, 11528 Athens, Greece; aggelikiandrikop{at}gmail.com
Citation
Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer
Publication history
- Received August 20, 2022
- Accepted December 14, 2022
- First published January 5, 2023.
Online issue publication
April 03, 2023
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.